Gilead Sciences Inc
NASDAQ: GILD
$83.94
+$0.04 (+0.0%)
Closing Price on September 20, 2024
GILD Articles
Vista Outdoor, Gilead Sciences, Fitbit, and Fossil posted new 52-week lows on Thursday.
Published:
Last Updated:
Gilead Sciences, Gale Biopharma, Teva, and Fitbit post new 52-week lows Wednesday.
Published:
Last Updated:
24/7 Wall St. has included some highlights from the Gilead Sciences earnings report, as well as what analysts are saying afterward.
Published:
Last Updated:
Not that many biotech and pharma companies were on the move Wednesday, but a few of the smaller caps made splash, while one giant company posted a massive loss.
Published:
Last Updated:
The op analyst upgrades, downgrades and initiations seen on Wednesday include Broadcom, Cheniere Energy, Gilead Sciences, Microchip Technology, Twitter, Lennar and Bankrate.
Published:
Last Updated:
Gilead Sciences Inc. (NASDAQ: GILD) reported its fourth-quarter earnings after the markets closed on Tuesday. The company posted $2.70 in earnings per share (EPS) and $7.3 billion in revenue,...
Published:
Last Updated:
Gilead Sciences is set to report its fourth-quarter financial results after the markets close on Tuesday.
Published:
Last Updated:
24/7 Wall St. has put together a preview of GM, Twitter, NVIDIA and some of the major companies reporting their quarterly results this week as earnings season winds down.
Published:
Last Updated:
With stocks at all-time highs, perhaps there may be some better safety in companies that are known and that offer "value" as well. It is this value segment that has come front and center.
Published:
Last Updated:
As we approached Trump’s inauguration, the health care sector in general rallied. Now it’s time to see what the bears have to say about this rally.
Published:
Last Updated:
DryShips, Gilead Sciences, BT Group, and Cascadian Therapeutics made new 52-week lows on Tuesday.
Published:
Last Updated:
DryShips, Teva, Endo Pharma, and Gilead Sciences posted new 52-week lows Monday.
Published:
Last Updated:
A new Jefferies research report makes the case that while market parameters are indeed expensive, there still are cheap stocks to buy that have a large enough market cap to provide some safety.
Published:
Last Updated:
As we have approached Trump’s inauguration, the health care sector in general has rallied. Now it’s time to see what the bears have to say about this rally.
Published:
Last Updated:
Needless to say, the past two years have been rough on biotech. The question for investors is which of the stocks hold the best potential in 2017.
Published:
Last Updated: